fampridine indications/contra

Stem definitionDrug idCAS RN
4163 504-24-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • fampyra
  • dalfampridine
  • ampyra
  • pyridin-4-amine
  • 4-aminopyridine
  • fampridine
One of the POTASSIUM CHANNEL BLOCKERS with secondary effect on calcium currents which is used mainly as a research tool and to characterize channel subtypes.
  • Molecular weight: 94.12
  • Formula: C5H6N2
  • CLOGP: 0.32
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 1
  • TPSA: 38.91
  • ALOGS: 0.46
  • ROTB: 0

Drug dosage:

DoseUnitRoute
20 mg O

Approvals:

DateAgencyCompanyOrphan
Jan. 22, 2010 FDA ACORDA

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Urinary tract infection 2338.97 35.69 705 6556 30623 3347975
Gait disturbance 2332.78 35.69 686 6575 27306 3351292
Drug ineffective 2094.15 35.69 910 6351 115180 3263418
Laboratory test abnormal 1635.78 35.69 377 6884 5467 3373131
Balance disorder 1302.49 35.69 366 6895 12073 3366525
Multiple sclerosis relapse 1166.92 35.69 333 6928 11597 3367001
Insomnia 1042.78 35.69 400 6861 35498 3343100
Fall 991.14 35.69 444 6817 58439 3320159
Dizziness 954.88 35.69 469 6792 76043 3302555
Seizure 697.71 35.69 311 6950 40089 3338509
Urine analysis abnormal 658.43 35.69 124 7137 589 3378009
Inappropriate schedule of drug administration 652.51 35.69 221 7040 13532 3365066
Muscular weakness 596.66 35.69 229 7032 20112 3358486
Therapy cessation 567.56 35.69 148 7113 3601 3374997
Multiple sclerosis 523.88 35.69 158 7103 6610 3371988
Asthenia 458.12 35.69 275 6986 65390 3313208
Headache 438.57 35.69 303 6958 91677 3286921
Fatigue 430.40 35.69 318 6943 106922 3271676
Therapeutic response unexpected 422.90 35.69 126 7135 5042 3373556
Adverse drug reaction 350.03 35.69 126 7135 9185 3369413
Nausea 328.06 35.69 294 6967 129351 3249247
Constipation 320.20 35.69 168 7093 30644 3347954
Gait inability 309.93 35.69 109 7152 7416 3371182
Drug dose omission 306.75 35.69 176 7085 38256 3340342
Back pain 284.56 35.69 167 7094 37838 3340760
Paraesthesia 274.17 35.69 146 7115 27402 3351196
Memory impairment 262.96 35.69 117 7144 14821 3363777
Escherichia urinary tract infection 248.23 35.69 62 7199 1255 3377343
Feeling abnormal 246.36 35.69 136 7125 27389 3351209
B-lymphocyte count decreased 235.10 35.69 42 7219 138 3378460

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC N07XX07 NERVOUS SYSTEM
OTHER NERVOUS SYSTEM DRUGS
OTHER NERVOUS SYSTEM DRUGS
Other nervous system drugs
FDA EPC N0000192795 Potassium Channel Blocker
FDA MoA N0000175448 Potassium Channel Antagonists
MeSH PA D002317 Cardiovascular Agents
MeSH PA D049990 Membrane Transport Modulators
MeSH PA D026902 Potassium Channel Blockers
CHEBI has role CHEBI:71031 orphan drug
CHEBI has role CHEBI:33289 avicide

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Multiple sclerosis indication 24700007 DOID:2377
Seizure disorder contraindication 128613002 DOID:1826
Impaired renal function disorder contraindication 197663003

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.58 Basic

Orange Book patent data (new drug applications)

scroll-->
Formulation strengthTrade nameApplicantApplication numberApproval dateTypeDose formRoutePatent numberPatent expiration datePatent use
10MG AMPYRA ACORDA N022250 Jan. 22, 2010 RX TABLET, EXTENDED RELEASE ORAL 5540938 July 30, 2018 IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
10MG AMPYRA ACORDA N022250 Jan. 22, 2010 RX TABLET, EXTENDED RELEASE ORAL 8663685 Jan. 18, 2025 IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
10MG AMPYRA ACORDA N022250 Jan. 22, 2010 RX TABLET, EXTENDED RELEASE ORAL 8440703 April 8, 2025 IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
10MG AMPYRA ACORDA N022250 Jan. 22, 2010 RX TABLET, EXTENDED RELEASE ORAL 8354437 Dec. 22, 2026 IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)
10MG AMPYRA ACORDA N022250 Jan. 22, 2010 RX TABLET, EXTENDED RELEASE ORAL 8007826 May 26, 2027 IMPROVEMENT OF WALKING IN PATIENTS WITH MULTIPLE SCLEROSIS (MS)

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Voltage-gated potassium channel Ion channel BLOCKER CHEMBL CHEMBL
Potassium voltage-gated channel subfamily C member 1 Unclassified BLOCKER IC50 4.50 IUPHAR
Potassium voltage-gated channel subfamily C member 2 Unclassified BLOCKER IC50 4.60 IUPHAR

External reference:

scroll-->
IDSource
2416 IUPHAR_LIGAND_ID
4029704 VUID
N0000180628 NUI
C0000477 UMLSCUI
D04127 KEGG_DRUG
CHEMBL284348 ChEMBL_ID
80994002 SNOMEDCT_US
413355004 SNOMEDCT_US
NOCODE MMSL
4025700 VANDF
4025705 VANDF
897018 RXNORM
26967 MMSL
d07546 MMSL
4029704 VANDF
N0000167244 NDFRT
N0000180628 NDFRT
N0000176193 NDFRT
N0000176063 NDFRT
006829 NDDF
BH3B64OKL9 UNII
7283 INN_ID
DB06637 DRUGBANK_ID
1727 PUBCHEM_CID
D015761 MESH_DESCRIPTOR_UI
CHEBI:34385 CHEBI

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
AMPYRA HUMAN PRESCRIPTION DRUG LABEL 1 10144-427 TABLET, FILM COATED, EXTENDED RELEASE 10 mg ORAL NDA 18 sections